
Retinitis Pigmentosa (Retinitis) - Pipeline Insight, 2024
Description
Retinitis Pigmentosa (Retinitis) - Pipeline Insight, 2024
DelveInsight’s, “Retinitis Pigmentosa - Pipeline Insight, 2024,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Retinitis Pigmentosa: Overview
Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa.
""Retinitis Pigmentosa - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided which includes the disease overview and Retinitis Pigmentosa treatment guidelines. The assessment part of the report embraces, in depth Retinitis Pigmentosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve Retinitis Pigmentosa.
This segment of the Retinitis Pigmentosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Retinitis Pigmentosa Emerging Drugs
- BIIB-112: Biogen
- QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
Further product details are provided in the report……..
Retinitis Pigmentosa: Therapeutic Assessment
This segment of the report provides insights about the different Retinitis Pigmentosa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Retinitis Pigmentosa
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Retinitis Pigmentosa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinitis Pigmentosa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinitis Pigmentosa drugs.
Retinitis Pigmentosa Report Insights
- Retinitis Pigmentosa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Retinitis Pigmentosa drugs?
- How many Retinitis Pigmentosa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinitis Pigmentosa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinitis Pigmentosa therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Retinitis Pigmentosa and their status?
- What are the key designations that have been granted to the emerging drugs?
- Biogen
- Neurotech
- Ionis Pharmaceuticals
- Novartis Pharmaceuticals
- Nacuity Pharmaceuticals
- ReNeuron
- ID Pharma
- Allegro Ophthalmics
- SparingVision
- Editas Medicine
- OiDE OptoEye
- BIIB-112
- NT 501
- QR 1123 (formerly ISIS RHO 2.5Rx)
- CPK 850
- N-acetylcysteine-amide
- ReN 003
- DVC1-0401
- Risuteganib
- SPVN 06
- SPVN 20
- LCA10 program
- GtCCR4 gene therapy
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Retinitis Pigmentosa: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Retinitis Pigmentosa companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Retinitis Pigmentosa Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- BIIB-112: Biogen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- N-acetylcysteine-amide: Nacuity Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- SPVN 06: SparingVision
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Retinitis Pigmentosa Key Companies
- Retinitis Pigmentosa Key Products
- Retinitis Pigmentosa- Unmet Needs
- Retinitis Pigmentosa- Market Drivers and Barriers
- Retinitis Pigmentosa- Future Perspectives and Conclusion
- Retinitis Pigmentosa Analyst Views
- Retinitis Pigmentosa Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.